WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

@article{Allgulander2003WCARF,
  title={WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder},
  author={C. Allgulander and B. Bandelow and E. Hollander and S. Montgomery and D. Nutt and A. Okasha and M. Pollack and Dan J Stein and R. Swinson},
  journal={CNS Spectrums},
  year={2003},
  volume={8},
  pages={53 - 61}
}
ABSTRACT What are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4% to 7% in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also… Expand
Generalized anxiety disorder: how to treat, and for how long?
  • R. Lam
  • Medicine
  • International journal of psychiatry in clinical practice
  • 2006
TLDR
Data from recent relapse-prevention studies and longer-term maintenance studies with paroxetine, venlafaxine and escitalopram strongly support the value of continued treatment for at least a further 6 months, and issues relating to the natural course of GAD are highlighted as important considerations to guide selection of pharmacotherapy. Expand
Generalized anxiety disorder: What are we missing?
TLDR
Physicians require more long-term data, including that on the influence of ethnicity and genetics, to assist them to better understand and more effectively manage GAD. Expand
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
TLDR
An algorithm for the psychopharmacologic management of GAD is presented, intended for all clinicians who treat patients with GAD, where issues of pharmacotherapy are under consideration, taking into account salient symptomatology and comorbidity, levels of evidence and extent of response. Expand
Generalized anxiety disorder.
Abstract Generalized anxiety disorder (GAD) is common in clinical practice. Most cases are comorbid with another Axis I disorder, notably mood disorders like major depressive disorder and bipolarExpand
Persistent depression and anxiety in the United States: prevalence and quality of care.
TLDR
Strategies are needed to increase treatment use and intensity for people with persistent depressive and anxiety disorders, which may require improved access to mental health specialists. Expand
Duration of Untreated Illness as a Predictor of Treatment Response and Clinical Course in Generalized Anxiety Disorder
TLDR
Results from this preliminary study seem to suggest that a shorter DUI-AD may determine a better response to pharmacologic treatment in patients with GAD, and that a longer DUI (DUI-BDZ and DUI- AD) may be associated to a worse clinical course. Expand
The Burden of Generalized Anxiety Disorder in Germany
Objective: To review studies quantifying the burden of generalized anxiety disorder (GAD) in Germany. Methods: A review of 17 original English-language studies on the human, health care and economicExpand
Long-term outcome of anxiety disorders: a review of double-blind studies
TLDR
There is no predictor to identify those patients who require long-term pharmacotherapy for anxiety disorders, and naturalistic studies in anxiety disorders indicate that the relapse risk after discontinuation is not associated with the treatment duration. Expand
Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms
TLDR
It is suggested that pregabalin, as part of a combination regimen with antidepressants and/or benzodiazepines, might be effective for the treatment of patients with GAD who have shown inadequate response to previous antidepressants and have severe depressive symptoms. Expand
[Pharmacological treatment of generalized anxiety disorders: rationale and limitations].
TLDR
It is important to realize that most clinical trials in this field only include patients with non-comorbid generalized anxiety and that their conclusion may not always be generalizable to most psychiatric patients who are usually characterized by a high rate of comorbidity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Long‐term pharmacological treatment of generalized anxiety disorder
TLDR
Only eight long‐term reports of studies conducted in well‐defined homogeneous groups of patients diagnosed with generalized anxiety disorder were found with the methodology of these studies presenting a number of limiting factors, and results are inconclusive and no reference drug could be identified. Expand
The epidemiology of generalized anxiety disorder.
TLDR
The weight of evidence reviewed here argues against the view expressed by early commentators that GAD is better conceptualized as a prodrome, residual, or severity marker of other disorders than as an independent disorder, and shows that the status of GAD as a independent disorder is at least as strongly supported by available evidence as is that of other anxiety or mood disorders. Expand
Generalized anxiety disorder. Longitudinal course and pharmacologic treatment.
  • E. Schweizer
  • Psychology, Medicine
  • The Psychiatric clinics of North America
  • 1995
TLDR
The pharmacologic treatment of GAD should be conceptualized from the first day of treatment in terms of the long-term nature of the illness, in much the same way that treatment of affective disorders is now conceptualized. Expand
Chronic anxiety: deciding the length of treatment.
TLDR
Establishing a secure and specific diagnosis and ruling out concomitant psychiatric and medical illnesses will augment the success of pharmacotherapy and nonpharmacologic techniques may well supplement medication trials. Expand
Chronic anxiety: deciding the length of treatment.
: Anxiety disorders are chronic illnesses requiring long-term treatment. Relapse is typical and should not be considered treatment failure. Although the general guiding principle of pharmacotherapyExpand
An overview of generalized anxiety disorder: disease state--appropriate therapy.
TLDR
Generalized anxiety disorder is differentiated from adjustment disorder with anxiety because only GAD can manifest without identifiable emotional stressors, and use of benzodiazepines in long-term treatment is usually ill-advised. Expand
Psychological treatment of generalised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980.
  • R. Durham, T. Allan
  • Psychology, Medicine
  • The British journal of psychiatry : the journal of mental science
  • 1993
TLDR
A balanced appraisal of the value of psychological therapy with this common condition requires a fuller description of sample characteristics and more systematic investigation of the clinical significance of treatment effects over the long term. Expand
Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder
  • J. Kelsey
  • Psychology, Medicine
  • Depression and anxiety
  • 2000
TLDR
Treatment with antidepressants, though associated with a longer onset of action than benzodiazepines, does not produce physiological dependency, and is useful in a patient population with a high prevalence of mood disorders. Expand
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
TLDR
This first placebo-controlled demonstration of the long-term efficacy of any drug class in treating outpatients with DSM-IV-diagnosed GAD shows venlafaxine XR is an effective, rapidly acting, safe, once-daily agent for both the short- and long- term treatment of anxiety and may provide an important alternative to currently available anxiolytics. Expand
Pharmacotherapy of generalized anxiety disorder.
  • J. Davidson
  • Medicine
  • The Journal of clinical psychiatry
  • 2001
TLDR
Treatment with antidepressants has opened up a new area of investigation into the pharmacotherapy of GAD, with a growing body of evidence supporting the role of therapies such as paroxetine and venlafaxine extended release. Expand
...
1
2
3
4
5
...